[1] 马培奇.新颖蛋白结合微粒药物紫杉醇新制剂Abraxane在美首次获准上市[J].中国医药技术与市场,2005,6:1-3.

[2] 颜子力.Abraxane获准用于部分非小细胞肺癌患者[EB/OL].http://drug.39.net/a/121016/4067495.html,2012-10-16.

[3] fuchengyi.FDA 批准 Abraxane 晚期胰腺癌新适应症[EB/OL].http://oncol.dxy.cn/article/58956,2013-09-07.

[4] Desai Neil,Trieu Vuong,Yao Zhiwen et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.[J] .Clin. Cancer Res., 2006, 12: 1317-24.

[5] Gradishar William J,Krasnojon Dimitry,Cheporov Sergey et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.[J] .J. Clin. Oncol., 2009, 27: 3611-9.

[6] van Zuylen L,Verweij J,Sparreboom A,Role of formulation vehicles in taxane pharmacology.[J] .Invest New Drugs, 2001, 19: 125-41.

[7]  van Tellingen O,Beijnen J H,Verweij J et al. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.[J] .Clin. Cancer Res., 1999, 5: 2918-24.

[8] Ellis A G,Crinis N A,Webster L K,Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80.[J] .Cancer Chemother. Pharmacol., 1996, 38: 81-7.

[9] No authors Listed.ONS News.2004;19(suppl 9):75-76

[10] 注射用紫杉醇（白蛋白结合型）说明书。2018.10.12

[11] 陈斌斌, 范长生. 注射用紫杉醇(白蛋白结合型)治疗晚期乳腺癌的预算影响分析[J]. 中国医疗保险, 2016(12):60-63.

[12] Adams S,Diamond Jennifer R,Hamilton E, et al. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.[J] .JAMA Oncol, 2018.

[13] Schmid Peter,Adams Sylvia,Rugo Hope S, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.[J] .N. Engl. J. Med., 2018, 379: 2108-2121.